Molecule
Barium sulfate is a radiographic contrast agent indicated in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract (GI) in adult and pediatric patients. MedsAcross supplies Barium sulfate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
E-Z-PAQUE is indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract (GI) in adult and pediatric patients. E-Z-PAQUE is a radiographic contrast agent indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients
Source: US FDA prescribing information
Due to its high atomic number, barium (the active ingredient in E-Z-PAQUE) is opaque to x-rays and therefore acts as a positive contrast agent for radiographic studies.
Source: US FDA prescribing information
Adults: Recommended reconstituted oral dose is between 150 – 750 mL. Pediatric patients: adjust reconstituted dose based on relative GI volume. Must reconstitute supplied powder with water prior to use. See Full Prescribing Information for reconstitution instructions
Source: US FDA prescribing information
E-Z-PAQUE is contraindicated in patients with the following conditions: Known or suspected perforation of the GI tract Known obstruction of the GI tract High risk of GI perforation such as those with a recent prior GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to the pelvis High risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation With known severe hypersensitivity to barium sulfate or any of the excipients of E-Z-PAQUE Known or suspected perforation of the GI tract. Known obstruction of the GI tract.
Source: US FDA prescribing information
Hypersensitivity reactions: Emergency equipment and trained personnel should be immediately available. Intra-abdominal barium leakage: May occur in conditions such as GI fistula, ulcer, inflammatory bowel disease, appendicitis or diverticulitis, severe stenosis or obstructing lesions of the GI tract. Delayed GI transit and obstruction: Patients should maintain adequate hydration in days following a barium sulfate procedure to avoid obstruction or impaction caused by baroliths. Aspiration pneumonitis: Patients with history of food aspiration or with swallowing disorders are at increased risk.
Source: US FDA prescribing information
The following adverse reactions have been identified from spontaneous reporting or clinical studies of barium sulfate administered orally. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure Nausea, vomiting, diarrhea and abdominal cramping Serious adverse reactions and fatalities include aspiration pneumonitis, barium sulfate impaction, intestinal perforation with consequent peritonitis and granuloma formation, vasovagal and syncopal episodes Common adverse reactions include nausea, vomiting, diarrhea and abdominal cramping
Source: US FDA prescribing information
Store at USP controlled room temperature 20 to 25°C (68 to 77° F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
16 presentations of Barium sulfate, sorted by availability.
15 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 11 January 2016 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 16 presentations of Barium sulfate and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 15 brand names for Barium sulfate, including E-Z-Disk, E-z-hd, E-Z-Paque, ENTERO Vu 24%, Readi-Cat 2, Readi-Cat 2 Banana Smoothie, Readi-Cat 2 Berry Smoothie, Readi-Cat 2 Creamy Vanilla Smoothie.
Yes. The US FDA first approved Barium sulfate on 11 January 2016, according to Drugs@FDA.
No listed presentation of Barium sulfate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.